+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Substance P Market - Global Forecast 2026-2032- Product Image
Substance P Market - Global Forecast 2026-2032- Product Image
Sale

Substance P Market - Global Forecast 2026-2032

  • Report

  • 188 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6158392
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Substance P: Biological Role and Translational Relevance

Substance P is an undecapeptide encoded by the TAC1 gene and best known as an endogenous ligand of the neurokinin-1 (NK1) receptor. It participates in nociception, neurogenic inflammation, vasodilation, smooth-muscle activity, emesis, immune signaling, and stress-related neural pathways. Its effects vary by tissue, receptor expression, concentration, and interactions with other mediators, making biological context essential when interpreting research findings.

From Pain Mediator to Multisystem Signaling Target

Research has broadened beyond Substance P’s classical role in pain transmission. The pathway is being examined in inflammatory and allergic conditions, gastrointestinal and respiratory biology, oncology, neuropsychiatric disorders, wound responses, and host-immune communication. This shift has encouraged more selective study designs that distinguish peripheral from central signaling and evaluate Substance P alongside related tachykinins, cytokines, and sensory-neuron activity.

Artificial Intelligence Accelerates Substance P Research

Artificial intelligence can support Substance P research by integrating transcriptomic, proteomic, imaging, pharmacological, and clinical datasets. Machine-learning methods may help identify NK1-receptor expression patterns, predict ligand-receptor interactions, stratify experimental models, and prioritize therapeutic hypotheses. These applications remain dependent on high-quality, comparable datasets and careful validation, because biological heterogeneity, assay differences, and limited clinical translation can produce misleading associations.

Regional Research Priorities Across the Global Landscape

North America has strong activity in neurobiology, pain science, drug discovery, and translational medicine. Europe emphasizes mechanistic pharmacology, inflammation, clinical research, and regulatory-quality evidence. Asia-Pacific combines expanding biomedical capacity with substantial interest in neuroscience, traditional-medicine interfaces, and precision therapeutics. Latin America contributes research on infectious disease, inflammation, and public-health applications, while the Middle East is developing clinical and molecular research capability. Africa’s priorities include locally relevant studies of pain, inflammation, infectious disease, and health-system access; collaboration, biobanking, and infrastructure remain important enablers across the region.

Collaborative Group Dynamics Shape Research and Regulation

ASEAN research priorities reflect regional collaboration in biomedical science, infectious disease, and emerging clinical infrastructure. BRICS members span major research systems with varied strengths in pharmacology, neuroscience, biotechnology, and population health. The European Union benefits from cross-border research frameworks and harmonized regulatory structures, while the G7 contributes substantial expertise in advanced medicine, translational science, and data-intensive biology. GCC countries are investing in healthcare modernization and research capacity, and NATO-linked collaboration can support standards, preparedness, and biomedical knowledge exchange without defining a single Substance P research agenda.

Country-Level Capabilities and Applications

Australia supports neuroscience, immunology, and clinical research; Brazil contributes expertise in inflammation, infectious disease, and public health; Canada is active in pain, neurobiology, and translational research. China and India are expanding molecular, pharmaceutical, and clinical capabilities, while Japan and South Korea contribute advanced biomedical engineering and neuroscience programs. France, Germany, Italy, Spain, and the United Kingdom maintain established research ecosystems spanning pharmacology, neurology, inflammation, and clinical investigation. Mexico supports research connected to pain, infectious disease, and health services. Russia has capabilities in biomedical and pharmacological research, although collaboration conditions and access to international networks can vary. The United States remains a major contributor across basic, translational, and clinical Substance P studies.

Priorities for Leaders in Substance P Research and Development

Industry leaders should define applications around validated biological mechanisms rather than treating Substance P as a universal disease marker. Investment priorities include reproducible assays, clinically relevant biomarkers, selective NK1-pathway modulation, and study designs that separate central and peripheral effects. Partnerships with academic and clinical centers can improve access to well-characterized samples and longitudinal outcomes. Organizations should also establish governance for artificial-intelligence use, including data provenance, bias assessment, external validation, and transparent reporting of negative or inconclusive results.

Evidence-Based Methodology for the Executive Summary

This summary uses the supplied market topic as a scientific domain and synthesizes established biological knowledge concerning Substance P, TAC1, tachykinin signaling, and the NK1 receptor. The assessment is structured across mechanisms, applications, enabling technologies, geography, and collaborative groupings. It intentionally excludes market estimates, market sizing, market shares, forecasts, and company-specific claims. Regional, group, and country narratives are qualitative and should be validated against current peer-reviewed literature, clinical-trial records, regulatory publications, and national research data before investment or policy decisions.

Substance P Remains a Context-Dependent Translational Opportunity

Substance P is a well-established signaling molecule with relevance across pain, inflammation, neural communication, and immune biology. Its future importance will depend on sharper patient and pathway stratification, stronger mechanistic validation, and disciplined translation from experimental models to clinical outcomes. Advances in multi-omics, imaging, computational analysis, and collaborative research may improve understanding, but durable progress requires reproducibility, clinically meaningful endpoints, and cautious interpretation of complex biology.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Substance P Market, by Therapeutic Applications
8.1. Introduction
8.2. Inflammatory Disorders
8.3. Neurological Disorders
8.4. Pain Management
8.4.1. Acute Pain
8.4.2. Chronic Pain
8.5. Psychiatric Conditions
9. Substance P Market, by Research And Development
9.1. Introduction
9.2. Biomarker Identification
9.2.1. Protein Expression Studies
9.2.2. Signal Transduction Analysis
9.3. Clinical Studies
9.4. Mechanism Of Action
9.5. Preclinical Research
10. Substance P Market, by Product Formulations
10.1. Introduction
10.2. Injectable Formulations
10.2.1. Sustained Release Injections
10.3. Nasal Sprays
10.4. Oral Formulations
10.5. Transdermal Systems
11. Substance P Market, by Delivery Technologies
11.1. Introduction
11.2. Liposomal Delivery
11.3. Nanotechnology
11.3.1. Future Nanocarriers
11.4. Polymer Based Systems
12. Substance P Market, by Institutional Collaborations
12.1. Introduction
12.2. Clinical Research Centers
12.3. Contract Research Organizations
12.4. University Laboratories
13. Substance P Market, by Industry Stakeholders
13.1. Introduction
13.2. Biopharmaceutical Companies
13.2.1. Large Enterprises
13.2.2. Mid-Size Organizations
13.3. Biotechnology Firms
13.4. Specialized Startups
14. Substance P Market, by Regulatory And Policy
14.1. Introduction
14.2. Approval Frameworks
14.2.1. Fast Track Approvals
14.2.2. Standard Reviews
14.3. Reimbursement Strategies
14.4. Safety And Compliance Monitoring
15. Americas Substance P Market
15.1. Introduction
15.2. Argentina
15.3. Brazil
15.4. Canada
15.5. Mexico
15.6. United States
16. Asia-Pacific Substance P Market
16.1. Introduction
16.2. Australia
16.3. China
16.4. India
16.5. Indonesia
16.6. Japan
16.7. Malaysia
16.8. Philippines
16.9. Singapore
16.10. South Korea
16.11. Taiwan
16.12. Thailand
16.13. Vietnam
17. Europe, Middle East & Africa Substance P Market
17.1. Introduction
17.2. Denmark
17.3. Egypt
17.4. Finland
17.5. France
17.6. Germany
17.7. Israel
17.8. Italy
17.9. Netherlands
17.10. Nigeria
17.11. Norway
17.12. Poland
17.13. Qatar
17.14. Russia
17.15. Saudi Arabia
17.16. South Africa
17.17. Spain
17.18. Sweden
17.19. Switzerland
17.20. Turkey
17.21. United Arab Emirates
17.22. United Kingdom
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Advanced BioPharma Research
18.3.2. Advanced Neuro Technologies
18.3.3. Advanced Research Peptides
18.3.4. BioActive Pharmaceuticals Corp.
18.3.5. Biological Peptide Technologies
18.3.6. BioNanoScience Inc.
18.3.7. BioSignal Innovations Inc.
18.3.8. Biotech Regulatory Research
18.3.9. CNS Biologicals
18.3.10. CNS Therapeutics Inc.
18.3.11. Critical BioPharmaceuticals
18.3.12. Genetic Neuro Innovations
18.3.13. Innovative Neuro Research LLC
18.3.14. Innovative NeuroPeptide Solutions
18.3.15. Innovative Substance Products
18.3.16. LifeScience Neuro Labs
18.3.17. Molecular Bio Innovations
18.3.18. NeuroBioTech Inc.
18.3.19. NeuroDynamics Research Group
18.3.20. NeuroMedical Biomolecules Inc.
18.3.21. Neuropeptide Integrations LLC
18.3.22. Neuropeptide Therapeutics
18.3.23. NeuroPharm Solutions
18.3.24. NeuroPlex Pharmaceuticals
18.3.25. NeuroResearch and Therapies
18.3.26. NeuroSynTech Solutions
18.3.27. NextGen NeuroScience
18.3.28. Peptide Renaissance Inc.
18.3.29. Peptide Research Institute
18.3.30. Peptide Synthesis Solutions
18.3.31. Peptide Technology Innovators
18.3.32. PeptidePlus Biologics
18.3.33. PharmaNeuro Solutions Ltd.
18.3.34. Precision Pharma Research
18.3.35. Substance P BioSciences
18.3.36. Synthetic Peptide Labs
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. SUBSTANCE P MARKET MULTI-CURRENCY
FIGURE 2. SUBSTANCE P MARKET MULTI-LANGUAGE
FIGURE 3. SUBSTANCE P MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL SUBSTANCE P MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL SUBSTANCE P MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL SUBSTANCE P MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL SUBSTANCE P MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL SUBSTANCE P MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL SUBSTANCE P MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2024 VS 2030 (%)
FIGURE 10. GLOBAL SUBSTANCE P MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL SUBSTANCE P MARKET SIZE, BY PRODUCT FORMULATIONS, 2024 VS 2030 (%)
FIGURE 12. GLOBAL SUBSTANCE P MARKET SIZE, BY PRODUCT FORMULATIONS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL SUBSTANCE P MARKET SIZE, BY DELIVERY TECHNOLOGIES, 2024 VS 2030 (%)
FIGURE 14. GLOBAL SUBSTANCE P MARKET SIZE, BY DELIVERY TECHNOLOGIES, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL SUBSTANCE P MARKET SIZE, BY INSTITUTIONAL COLLABORATIONS, 2024 VS 2030 (%)
FIGURE 16. GLOBAL SUBSTANCE P MARKET SIZE, BY INSTITUTIONAL COLLABORATIONS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL SUBSTANCE P MARKET SIZE, BY INDUSTRY STAKEHOLDERS, 2024 VS 2030 (%)
FIGURE 18. GLOBAL SUBSTANCE P MARKET SIZE, BY INDUSTRY STAKEHOLDERS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL SUBSTANCE P MARKET SIZE, BY REGULATORY AND POLICY, 2024 VS 2030 (%)
FIGURE 20. GLOBAL SUBSTANCE P MARKET SIZE, BY REGULATORY AND POLICY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS SUBSTANCE P MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS SUBSTANCE P MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES SUBSTANCE P MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES SUBSTANCE P MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC SUBSTANCE P MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC SUBSTANCE P MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. EUROPE, MIDDLE EAST & AFRICA SUBSTANCE P MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. EUROPE, MIDDLE EAST & AFRICA SUBSTANCE P MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. SUBSTANCE P MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. SUBSTANCE P MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. SUBSTANCE P MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL SUBSTANCE P MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL SUBSTANCE P MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL SUBSTANCE P MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL SUBSTANCE P MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL SUBSTANCE P MARKET SIZE, BY INFLAMMATORY DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL SUBSTANCE P MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL SUBSTANCE P MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL SUBSTANCE P MARKET SIZE, BY ACUTE PAIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL SUBSTANCE P MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL SUBSTANCE P MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL SUBSTANCE P MARKET SIZE, BY PSYCHIATRIC CONDITIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL SUBSTANCE P MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL SUBSTANCE P MARKET SIZE, BY BIOMARKER IDENTIFICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL SUBSTANCE P MARKET SIZE, BY PROTEIN EXPRESSION STUDIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL SUBSTANCE P MARKET SIZE, BY SIGNAL TRANSDUCTION ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL SUBSTANCE P MARKET SIZE, BY BIOMARKER IDENTIFICATION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL SUBSTANCE P MARKET SIZE, BY CLINICAL STUDIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL SUBSTANCE P MARKET SIZE, BY MECHANISM OF ACTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL SUBSTANCE P MARKET SIZE, BY PRECLINICAL RESEARCH, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL SUBSTANCE P MARKET SIZE, BY PRODUCT FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL SUBSTANCE P MARKET SIZE, BY INJECTABLE FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL SUBSTANCE P MARKET SIZE, BY SUSTAINED RELEASE INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL SUBSTANCE P MARKET SIZE, BY INJECTABLE FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL SUBSTANCE P MARKET SIZE, BY NASAL SPRAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL SUBSTANCE P MARKET SIZE, BY ORAL FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL SUBSTANCE P MARKET SIZE, BY TRANSDERMAL SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL SUBSTANCE P MARKET SIZE, BY DELIVERY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL SUBSTANCE P MARKET SIZE, BY LIPOSOMAL DELIVERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL SUBSTANCE P MARKET SIZE, BY NANOTECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL SUBSTANCE P MARKET SIZE, BY FUTURE NANOCARRIERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL SUBSTANCE P MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL SUBSTANCE P MARKET SIZE, BY POLYMER BASED SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL SUBSTANCE P MARKET SIZE, BY INSTITUTIONAL COLLABORATIONS, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL SUBSTANCE P MARKET SIZE, BY CLINICAL RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL SUBSTANCE P MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL SUBSTANCE P MARKET SIZE, BY UNIVERSITY LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL SUBSTANCE P MARKET SIZE, BY INDUSTRY STAKEHOLDERS, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL SUBSTANCE P MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL SUBSTANCE P MARKET SIZE, BY LARGE ENTERPRISES, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL SUBSTANCE P MARKET SIZE, BY MID-SIZE ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL SUBSTANCE P MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL SUBSTANCE P MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL SUBSTANCE P MARKET SIZE, BY SPECIALIZED STARTUPS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL SUBSTANCE P MARKET SIZE, BY REGULATORY AND POLICY, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL SUBSTANCE P MARKET SIZE, BY APPROVAL FRAMEWORKS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL SUBSTANCE P MARKET SIZE, BY FAST TRACK APPROVALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL SUBSTANCE P MARKET SIZE, BY STANDARD REVIEWS, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL SUBSTANCE P MARKET SIZE, BY APPROVAL FRAMEWORKS, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL SUBSTANCE P MARKET SIZE, BY REIMBURSEMENT STRATEGIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL SUBSTANCE P MARKET SIZE, BY SAFETY AND COMPLIANCE MONITORING, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS SUBSTANCE P MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS SUBSTANCE P MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS SUBSTANCE P MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS SUBSTANCE P MARKET SIZE, BY BIOMARKER IDENTIFICATION, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS SUBSTANCE P MARKET SIZE, BY PRODUCT FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS SUBSTANCE P MARKET SIZE, BY INJECTABLE FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS SUBSTANCE P MARKET SIZE, BY DELIVERY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS SUBSTANCE P MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS SUBSTANCE P MARKET SIZE, BY INSTITUTIONAL COLLABORATIONS, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS SUBSTANCE P MARKET SIZE, BY INDUSTRY STAKEHOLDERS, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS SUBSTANCE P MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS SUBSTANCE P MARKET SIZE, BY REGULATORY AND POLICY, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS SUBSTANCE P MARKET SIZE, BY APPROVAL FRAMEWORKS, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS SUBSTANCE P MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 67. ARGENTINA SUBSTANCE P MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 68. ARGENTINA SUBSTANCE P MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 69. ARGENTINA SUBSTANCE P MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 70. ARGENTINA SUBSTANCE P MARKET SIZE, BY BIOMARKER IDENTIFICATION, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA SUBSTANCE P MARKET SIZE, BY PRODUCT FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA SUBSTANCE P MARKET SIZE, BY INJECTABLE FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA SUBSTANCE P MARKET SIZE, BY DELIVERY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA SUBSTANCE P MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA SUBSTANCE P MARKET SIZE, BY INSTITUTIONAL COLLABORATIONS, 2018-2030 (USD MILLION)
TABLE 76. ARGENTINA SUBSTANCE P MARKET SIZE, BY INDUSTRY STAKEHOLDERS, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA SUBSTANCE P MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA SUBSTANCE P MARKET SIZE, BY REGULATORY AND POLICY, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA SUBSTANCE P MARKET SIZE, BY APPROVAL FRAMEWORKS, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL SUBSTANCE P MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL SUBSTANCE P MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL SUBSTANCE P MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL SUBSTANCE P MARKET SIZE, BY BIOMARKER IDENTIFICATION, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL SUBSTANCE P MARKET SIZE, BY PRODUCT FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL SUBSTANCE P MARKET SIZE, BY INJECTABLE FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL SUBSTANCE P MARKET SIZE, BY DELIVERY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL SUBSTANCE P MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL SUBSTANCE P MARKET SIZE, BY INSTITUTIONAL COLLABORATIONS, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL SUBSTANCE P MARKET SIZE, BY INDUSTRY STAKEHOLDERS, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL SUBSTANCE P MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL SUBSTANCE P MARKET SIZE, BY REGULATORY AND POLICY, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL SUBSTANCE P MARKET SIZE, BY APPROVAL FRAMEWORKS, 2018-2030 (USD MILLION)
TABLE 93. CANADA SUBSTANCE P MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 94. CANADA SUBSTANCE P MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 95. CANADA SUBSTANCE P MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 96. CANADA SUBSTANCE P MARKET SIZE, BY BIOMARKER IDENTIFICATION, 2018-2030 (USD MILLION)
TABLE 97. CANADA SUBSTANCE P MARKET SIZE, BY PRODUCT FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 98. CANADA SUBSTANCE P MARKET SIZE, BY INJECTABLE FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 99. CANADA SUBSTANCE P MARKET SIZE, BY DELIVERY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 100. CANADA SUBSTANCE P MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 101. CANADA SUBSTANCE P MARKET SIZE, BY INSTITUTIONAL COLLABORATIONS, 2018-2030 (USD MILLION)
TABLE 102. CANADA SUBSTANCE P MARKET SIZE, BY INDUSTRY STAKEHOLDERS, 2018-2030 (USD MILLION)
TABLE 103. CANADA SUBSTANCE P MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 104. CANADA SUBSTANCE P MARKET SIZE, BY REGULATORY AND POLICY, 2018-2030 (USD MILLION)
TABLE 105. CANADA SUBSTANCE P MARKET SIZE, BY APPROVAL FRAMEWORKS, 2018-2030 (USD MILLION)
TABLE 106. MEXICO SUBSTANCE P MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 107. MEXICO SUBSTANCE P MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 108. MEXICO SUBSTANCE P MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 109. MEXICO SUBSTANCE P MARKET SIZE, BY BIOMARKER IDENTIFICATION, 2018-2030 (USD MILLION)
TABLE 110. MEXICO SUBSTANCE P MARKET SIZE, BY PRODUCT FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 111. MEXICO SUBSTANCE P MARKET SIZE, BY INJECTABLE FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 112. MEXICO SUBSTANCE P MARKET SIZE, BY DELIVERY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 113. MEXICO SUBSTANCE P MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 114. MEXICO SUBSTANCE P MARKET SIZE, BY INSTITUTIONAL COLLABORATIONS, 2018-2030 (USD MILLION)
TABLE 115. MEXICO SUBSTANCE P MARKET SIZE, BY INDUSTRY STAKEHOLDERS, 2018-2030 (USD MILLION)
TABLE 116. MEXICO SUBSTANCE P MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 117. MEXICO SUBSTANCE P MARKET SIZE, BY REGULATORY AND POLICY, 2018-2030 (USD MILLION)
TABLE 118. MEXICO SUBSTANCE P MARKET SIZE, BY APPROVAL FRAMEWORKS, 2018-2030 (USD MILLION)
TABLE 119. UNITED STATES SUBSTANCE P MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 120. UNITED STATES SUBSTANCE P MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 121. UNITED STATES SUBSTANCE P MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 122. UNITED STATES SUBSTANCE P MARKET SIZE, BY BIOMARKER IDENTIFICATION, 2018-2030 (USD MILLION)
TABLE 123. UNITED STATES SUBSTANCE P MARKET SIZE, BY PRODUCT FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 124. UNITED STATES SUBSTANCE P MARKET SIZE, BY INJECTABLE FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 125. UNITED STATES SUBSTANCE P MARKET SIZE, BY DELIVERY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 126. UNITED STATES SUBSTANCE P MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 127. UNITED STATES SUBSTANCE P MARKET SIZE, BY INSTITUTIONAL COLLABORATIONS, 2018-2030 (USD MILLION)
TABLE 128. UNITED STATES SUBSTANCE P MARKET SIZE, BY INDUSTRY STAKEHOLDERS, 2018-2030 (USD MILLION)
TABLE 129. UNITED STATES SUBSTANCE P MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 130. UNITED STATES SUBSTANCE P MARKET SIZE, BY REGULATORY AND POLICY, 2018-2030 (USD MILLION)
TABLE 131. UNITED STATES SUBSTANCE P MARKET SIZE, BY APPROVAL FRAMEWORKS, 2018-2030 (USD MILLION)
TABLE 132. UNITED STATES SUBSTANCE P MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 133. ASIA-PACIFIC SUBSTANCE P MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 134. ASIA-PACIFIC SUBSTANCE P MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 135. ASIA-PACIFIC SUBSTANCE P MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 136. ASIA-PACIFIC SUBSTANCE P MARKET SIZE, BY BIOMARKER IDENTIFICATION, 2018-2030 (USD MILLION)
TABLE 137. ASIA-PACIFIC SUBSTANCE P MARKET SIZE, BY PRODUCT FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 138. ASIA-PACIFIC SUBSTANCE P MARKET SIZE, BY INJECTABLE FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 139. ASIA-PACIFIC SUBSTANCE P MARKET SIZE, BY DELIVERY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 140. ASIA-PACIFIC SUBSTANCE P MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 141. ASIA-PACIFIC SUBSTANCE P MARKET SIZE, BY INSTITUTIONAL COLLABORATIONS, 2018-2030 (USD MILLION)
TABLE 142. ASIA-PACIFIC SUBSTANCE P MARKET SIZE, BY INDUSTRY STAKEHOLDERS, 2018-2030 (USD MILLION)
TABLE 143. ASIA-PACIFIC SUBSTANCE P MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 144. ASIA-PACIFIC SUBSTANCE P MARKET SIZE, BY REGULATORY AND POLICY, 2018-2030 (USD MILLION)
TABLE 145. ASIA-PACIFIC SUBSTANCE P MARKET SIZE, BY APPROVAL FRAMEWORKS, 2018-2030 (USD MILLION)
TABLE 146. ASIA-PACIFIC SUBSTANCE P MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 147. AUSTRALIA SUBSTANCE P MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 148. AUSTRALIA SUBSTANCE P MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 149. AUSTRALIA SUBSTANCE P MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 150. AUSTRALIA SUBSTANCE P MARKET SIZE, BY BIOMARKER IDENTIFICATION, 2018-2030 (USD MILLION)
TABLE 151. AUSTRALIA SUBSTANCE P MARKET SIZE, BY PRODUCT FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 152. AUSTRALIA SUBSTANCE P MARKET SIZE, BY INJECTABLE FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 153. AUSTRALIA SUBSTANCE P MARKET SIZE, BY DELIVERY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 154. AUSTRALIA SUBSTANCE P MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 155. AUSTRALIA SUBSTANCE P MARKET SIZE, BY INSTITUTIONAL COLLABORATIONS, 2018-2030 (USD MILLION)
TABLE 156. AUSTRALIA SUBSTANCE P MARKET SIZE, BY INDUSTRY STAKEHOLDERS, 2018-2030 (USD MILLION)
TABLE 157. AUSTRALIA SUBSTANCE P MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 158. AUSTRALIA SUBSTANCE P MARKET SIZE, BY REGULATORY AND POLICY, 2018-2030 (USD MILLION)
TABLE 159. AUSTRALIA SUBSTANCE P MARKET SIZE, BY APPROVAL FRAMEWORKS, 2018-2030 (USD MILLION)
TABLE 160. CHINA SUBSTANCE P MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 161. CHINA SUBSTANCE P MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 162. CHINA SUBSTANCE P MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 163. CHINA SUBSTANCE P MARKET SIZE, BY BIOMARKER IDENTIFICATION, 2018-2030 (USD MILLION)
TABLE 164. CHINA SUBSTANCE P MARKET SIZE, BY PRODUCT FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 165. CHINA SUBSTANCE P MARKET SIZE, BY INJECTABLE FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 166. CHINA SUBSTANCE P MARKET SIZE, BY DELIVERY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 167. CHINA SUBSTANCE P MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 168. CHINA SUBSTANCE P MARKET SIZE, BY INSTITUTIONAL COLLABORATIONS, 2018-2030 (USD MILLION)
TABLE 169. CHINA SUBSTANCE P MARKET SIZE, BY INDUSTRY STAKEHOLDERS, 2018-2030 (USD MILLION)
TABLE 170. CHINA SUBSTANCE P MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 171. CHINA SUBSTANCE P MARKET SIZE, BY REGULATORY AND POLICY, 2018-2030 (USD MILLION)
TABLE 172. CHINA SUBSTANCE P MARKET SIZE, BY APPROVAL FRAMEWORKS, 2018-2030 (USD MILLION)
TABLE 173. INDIA SUBSTANCE P MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 174. INDIA SUBSTANCE P MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 175. INDIA SUBSTANCE P MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 176. INDIA SUBSTANCE P MARKET SIZE, BY BIOMARKER IDENTIFICATION, 2018-2030 (USD MILLION)
TABLE 177. INDIA SUBSTANCE P MARKET SIZE, BY PRODUCT FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 178. INDIA SUBSTANCE P MARKET SIZE, BY INJECTABLE FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 179. INDIA SUBSTANCE P MARKET SIZE, BY DELIVERY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 180. INDIA SUBSTANCE P MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 181. INDIA SUBSTANCE P MARKET SIZE, BY INSTITUTIONAL COLLABORATIONS, 2018-2030 (USD MILLION)
TABLE 182. INDIA SUBSTANCE P MARKET SIZE, BY INDUSTRY STAKEHOLDERS, 2018-2030 (USD MILLION)
TABLE 183. INDIA SUBSTANCE P MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 184. INDIA SUBSTANCE P MARKET SIZE, BY REGULATORY AND POLICY, 2018-2030 (USD MILLION)
TABLE 185. INDIA SUBSTANCE P MARKET SIZE, BY APPROVAL FRAMEWORKS, 2018-2030 (USD MILLION)
TABLE 186. INDONESIA SUBSTANCE P MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 187. INDONESIA SUBSTANCE P MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 188. INDONESIA SUBSTANCE P MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 189. INDONESIA SUBSTANCE P MARKET SIZE, BY BIOMARKER IDENTIFICATION, 2018-2030 (USD MILLION)
TABLE 190. INDONESIA SUBSTANCE P MARKET SIZE, BY PRODUCT FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 191. INDONESIA SUBSTANCE P MARKET SIZE, BY INJECTABLE FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 192. INDONESIA SUBSTANCE P MARKET SIZE, BY DELIVERY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 193. INDONESIA SUBSTANCE P MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 194. INDONESIA SUBSTANCE P MARKET SIZE, BY INSTITUTIONAL COLLABORATIONS, 2018-2030 (USD MILLION)
TABLE 195. INDONESIA SUBSTANCE P MARKET SIZE, BY INDUSTRY STAKEHOLDERS, 2018-2030 (USD MILLION)
TABLE 196. INDONESIA SUBSTANCE P MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 197. INDONESIA SUBSTANCE P MARKET SIZE, BY REGULATORY AND POLICY, 2018-2030 (USD MILLION)
TABLE 198. INDONESIA SUBSTANCE P MARKET SIZE, BY APPROVAL FRAMEWORKS, 2018-2030 (USD MILLION)
TABLE 199. JAPAN SUBSTANCE P MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 200. JAPAN SUBSTANCE P MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 201. JAPAN SUBSTANCE P MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 202. JAPAN SUBSTANCE P MARKET SIZE, BY BIOMARKER IDENTIFICATION, 2018-2030 (USD MILLION)
TABLE 203. JAPAN SUBSTANCE P MARKET SIZE, BY PRODUCT FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 204. JAPAN SUBSTANCE P MARKET SIZE, BY INJECTABLE FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 205. JAPAN SUBSTANCE P MARKET SIZE, BY DELIVERY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 206. JAPAN SUBSTANCE P MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 207. JAPAN SUBSTANCE P MARKET SIZE, BY INSTITUTIONAL COLLABORATIONS, 2018-2030 (USD MILLION)
TABLE 208. JAPAN SUBSTANCE P MARKET SIZE, BY INDUSTRY STAKEHOLDERS, 2018-2030 (USD MILLION)
TABLE 209. JAPAN SUBSTANCE P MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 210. JAPAN SUBSTANCE P MARKET SIZE, BY REGULATORY AND POLICY, 2018-2030 (USD MILLION)
TABLE 211. JAPAN SUBSTANCE P MARKET SIZE, BY APPROVAL FRAMEWORKS, 2018-2030 (USD MILLION)
TABLE 212. MALAYSIA SUBSTANCE P MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 213. MALAYSIA SUBSTANCE P MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 214. MALAYSIA SUBSTANCE P MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 215. MALAYSIA SUBSTANCE P MARKET SIZE, BY BIOMARKER IDENTIFICATION, 2018-2030 (USD MILLION)
TABLE 216. MALAYSIA SUBSTANCE P MARKET SIZE, BY PRODUCT FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 217. MALAYSIA SUBSTANCE P MARKET SIZE, BY INJECTABLE FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 218. MALAYSIA SUBSTANCE P MARKET SIZE, BY DELIVERY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 219. MALAYSIA SUBSTANCE P MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 220. MALAYSIA SUBSTANCE P MARKET SIZE, BY INSTITUTIONAL COLLABORATIONS, 2018-2030 (USD MILLION)
TABLE 221. MALAYSIA SUBSTANCE P MARKET SIZE, BY INDUSTRY STAKEHOLDERS, 2018-2030 (USD MILLION)
TABLE 222. MALAYSIA SUBSTANCE P MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 223. MALAYSIA SUBSTANCE P MARKET SIZE, BY REGULATORY AND POLICY, 2018-2030 (USD MILLION)
TABLE 224. MALAYSIA SUBSTANCE P MARKET SIZE, BY APPROVAL FRAMEWORKS, 2018-2030 (USD MILLION)
TABLE 225. PHILIPPINES SUBSTANCE P MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 226. PHILIPPINES SUBSTANCE P MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 227. PHILIPPINES SUBSTANCE P MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 228. PHILIPPINES SUBSTANCE P MARKET SIZE, BY BIOMARKER IDENTIFICATION, 2018-2030 (USD MILLION)
TABLE 229. PHILIPPINES SUBSTANCE P MARKET SIZE, BY PRODUCT FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 230. PHILIPPINES SUBSTANCE P MARKET SIZE, BY INJECTABLE FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 231. PHILIPPINES SUBSTANCE P MARKET SIZE, BY DELIVERY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 232. PHILIPPINES SUBSTANCE P MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 233. PHILIPPINES SUBSTANCE P MARKET SIZE, BY INSTITUTIONAL COLLABORATIONS, 2018-2030 (USD MILLION)
TABLE 234. PHILIPPINES SUBSTANCE P MARKET SIZE, BY INDUSTRY STAKEHOLDERS, 2018-2030 (USD MILLION)
TABLE 235. PHILIPPINES SUBSTANCE P MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 236. PHILIPPINES SUBSTANCE P MARKET SIZE, BY REGULATORY AND POLICY, 2018-2030 (USD MILLION)
TABLE 237. PHILIPPINES SUBSTANCE P MARKET SIZE, BY APPROVAL FRAMEWORKS, 2018-2030 (USD MILLION)
TABLE 238. SINGAPORE SUBSTANCE P MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 239. SINGAPORE SUBSTANCE P MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 240. SINGAPORE SUBSTANCE P MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 241. SINGAPORE SUBSTANCE P MARKET SIZE, BY BIOMARKER IDENTIFICATION, 2018-2030 (USD MILLION)
TABLE 242. SINGAPORE SUBSTANCE P MARKET SIZE, BY PRODUCT FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 243. SINGAPORE SUBSTANCE P MARKET SIZE, BY INJECTABLE FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 244. SINGAPORE SUBSTANCE P MARKET SIZE, BY DELIVERY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 245. SINGAPORE SUBSTANCE P MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 246. SINGAPORE SUBSTANCE P MARKET SIZE, BY INSTITUTIONAL COLLABORATIONS, 2018-2030 (USD MILLION)
TABLE 247. SINGAPORE SUBSTANCE P MARKET SIZE, BY INDUSTRY STAKEHOLDERS, 2018-2030 (USD MILLION)
TABLE 248. SINGAPORE SUBSTANCE P MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 249. SINGAPORE SUBSTANCE P MARKET SIZE, BY REGULATORY AND POLICY, 2018-2030 (USD MILLION)
TABLE 250. SINGAPORE SUBSTANCE P MARKET SIZE, BY APPROVAL FRAMEWORKS, 2018-2030 (USD MILLION)
TABLE 251. SOUTH KOREA SUBSTANCE P MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 252. SOUTH KOREA SUBSTANCE P MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 253. SOUTH KOREA SUBSTANCE P MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 254. SOUTH KOREA SUBSTANCE P MARKET SIZE, BY BIOMARKER IDENTIFICATION, 2018-2030 (USD MILLION)
TABLE 255. SOUTH KOREA SUBSTANCE P MARKET SIZE, BY PRODUCT FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 256. SOUTH KOREA SUBSTANCE P MARKET SIZE, BY INJECTABLE FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 257. SOUTH KOREA SUBSTANCE P MARKET SIZE, BY DELIVERY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 258. SOUTH KOREA SUBSTANCE P MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 259. SOUTH KOREA SUBSTANCE P MARKET SIZE, BY INSTITUTIONAL COLLABORATIONS, 2018-2030 (USD MILLION)
TABLE 260. SOUTH KOREA SUBSTANCE P MARKET SIZE, BY INDUSTRY STAKEHOLDERS, 2018-2030 (USD MILLION)
TABLE 261. SOUTH KOREA SUBSTANCE P MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 262. SOUTH KOREA SUBSTANCE P MARKET SIZE, BY REGULATORY AND POLICY, 2018-2030 (USD MILLION)
TABLE 263. SOUTH KOREA SUBSTANCE P MARKET SIZE, BY APPROVAL FRAMEWORKS, 2018-2030 (USD MILLION)
TABLE 264. TAIWAN SUBSTANCE P MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 265. TAIWAN SUBSTANCE P MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 266. TAIWAN SUBSTANCE P MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 267. TAIWAN SUBSTANCE P MARKET SIZE, BY BIOMARKER IDENTIFICATION, 2018-2030 (USD MILLION)
TABLE 268. TAIWAN SUBSTANCE P MARKET SIZE, BY PRODUCT FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 269. TAIWAN SUBSTANCE P MARKET SIZE, BY INJECTABLE FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 270. TAIWAN SUBSTANCE P MARKET SIZE, BY DELIVERY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 271. TAIWAN SUBSTANCE P MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 272. TAIWAN SUBSTANCE P MARKET SIZE, BY INSTITUTIONAL COLLABORATIONS, 2018-2030 (USD MILLION)
TABLE 273. TAIWAN SUBSTANCE P MARKET SIZE, BY INDUSTRY STAKEHOLDERS, 2018-2030 (USD MILLION)
TABLE 274. TAIWAN SUBSTANCE P MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 275. TAIWAN SUBSTANCE P MARKET SIZE, BY REGULATORY AND POLICY, 2018-2030 (USD MILLION)
TABLE 276. TAIWAN SUBSTANCE P MARKET SIZE, BY APPROVAL FRAMEWORKS, 2018-2030 (USD MILLION)
TABLE 277. THAILAND SUBSTANCE P MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 278. THAILAND SUBSTANCE P MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 279. THAILAND SUBSTANCE P MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 280. THAILAND SUBSTANCE P MARKET SIZE, BY BIOMARKER IDENTIFICATION, 2018-2030 (USD MILLION)
TABLE 281. THAILAND SUBSTANCE P MARKET SIZE, BY PRODUCT FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 282. THAILAND SUBSTANCE P MARKET SIZE, BY INJECTABLE FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 283. THAILAND SUBSTANCE P MARKET SIZE, BY DELIVERY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 284. THAILAND SUBSTANCE P MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 285. THAILAND SUBSTANCE P MARKET SIZE, BY INSTITUTIONAL COLLABORATIONS, 2018-2030 (USD MILLION)
TABLE 286. THAILAND SUBSTANCE P MARKET SIZE, BY INDUSTRY STAKEHOLDERS, 2018-2030 (USD MILLION)
TABLE 287. THAILAND SUBSTANCE P MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 288. THAILAND SUBSTANCE P MARKET SIZE, BY REGULATORY AND POLICY, 2018-2030 (USD MILLION)
TABLE 289. THAILAND SUBSTANCE P MARKET SIZE, BY APPROVAL FRAMEWORKS, 2018-2030 (USD MILLION)
TABLE 290. VIETNAM SUBSTANCE P MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 291. VIETNAM SUBSTANCE P MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 292. VIETNAM SUBSTANCE P MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 293. VIETNAM SUBSTANCE P MARKET SIZE, BY BIOMARKER IDENTIFICATION, 2018-2030 (USD MILLION)
TABLE 294. VIETNAM SUBSTANCE P MARKET SIZE, BY PRODUCT FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 295. VIETNAM SUBSTANCE P MARKET SIZE, BY INJECTABLE FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 296. VIETNAM SUBSTANCE P MARKET SIZE, BY DELIVERY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 297. VIETNAM SUBSTANCE P MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 298. VIETNAM SUBSTANCE P MARKET SIZE, BY INSTITUTIONAL COLLABORATIONS, 2018-2030 (USD MILLION)
TABLE 299. VIETNAM SUBSTANCE P MARKET SIZE, BY INDUSTRY STAKEHOLDERS, 2018-2030 (USD MILLION)
TABLE 300. VIETNAM SUBSTANCE P MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 301. VIETNAM SUBSTANCE P MARKET SIZE, BY REGULATORY AND POLICY, 2018-2030 (USD MILLION)
TABLE 302. VIETNAM SUBSTANCE P MARKET SIZE, BY APPROVAL FRAMEWORKS, 2018-2030 (USD MILLION)
TABLE 303. EUROPE, MIDDLE EAST & AFRICA SUBSTANCE P MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 304. EUROPE, MIDDLE EAST & AFRICA SUBSTANCE P MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 305. EUROPE, MIDDLE EAST & AFRICA SUBSTANCE P MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 306. EUROPE, MIDDLE EAST & AFRICA SUBSTANCE P MARKET SIZE, BY BIOMARKER IDENTIFICATION, 2018-2030 (USD MILLION)
TABLE 307. EUROPE, MIDDLE EAST & AFRICA SUBSTANCE P MARKET SIZE, BY PRODUCT FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 308. EUROPE, MIDDLE EAST & AFRICA SUBSTANCE P MARKET SIZE, BY INJECTABLE FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 309. EUROPE, MIDDLE EAST & AFRICA SUBSTANCE P MARKET SIZE, BY DELIVERY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 310. EUROPE, MIDDLE EAST & AFRICA SUBSTANCE P MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 311. EUROPE, MIDDLE EAST & AFRICA SUBSTANCE P MARKET SIZE, BY INSTITUTIONAL COLLABORATIONS, 2018-2030 (USD MILLION)
TABLE 312. EUROPE, MIDDLE EAST & AFRICA SUBSTANCE P MARKET SIZE, BY INDUSTRY STAKEHOLDERS, 2018-2030 (USD MILLION)
TABLE 313. EUROPE, MIDDLE EAST & AFRICA SUBSTANCE P MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 314. EUROPE, MIDDLE EAST & AFRICA SUBSTANCE P MARKET SIZE, BY REGULATORY AND POLICY, 2018-2030 (USD MILLION)
TABLE 315. EUROPE, MIDDLE EAST & AFRICA SUBSTANCE P MARKET SIZE, BY APPROVAL FRAMEWORKS, 2018-2030 (USD MILLION)
TABLE 316. EUROPE, MIDDLE EAST & AFRICA SUBSTANCE P MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 317. DENMARK SUBSTANCE P MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 318. DENMARK SUBSTANCE P MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 319. DENMARK SUBSTANCE P MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 320. DENMARK SUBSTANCE P MARKET SIZE, BY BIOMARKER IDENTIFICATION, 2018-2030 (USD MILLION)
TABLE 321. DENMARK SUBSTANCE P MARKET SIZE, BY PRODUCT FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 322. DENMARK SUBSTANCE P MARKET SIZE, BY INJECTABLE FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 323. DENMARK SUBSTANCE P MARKET SIZE, BY DELIVERY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 324. DENMARK SUBSTANCE P MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 325. DENMARK SUBSTANCE P MARKET SIZE, BY INSTITUTIONAL COLLABORATIONS, 2018-2030 (USD MILLION)
TABLE 326. DENMARK SUBSTANCE P MARKET SIZE, BY INDUSTRY STAKEHOLDERS, 2018-2030 (USD MILLION)
TABLE 327. DENMARK SUBSTANCE P MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 328. DENMARK SUBSTANCE P MARKET SIZE, BY REGULATORY AND POLICY, 2018-2030 (USD MILLION)
TABLE 329. DENMARK SUBSTANCE P MARKET SIZE, BY APPROVAL FRAMEWORKS, 2018-2030 (USD MILLION)
TABLE 330. EGYPT SUBSTANCE P MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 331. EGYPT SUBSTANCE P MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 332. EGYPT SUBSTANCE P MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 333. EGYPT SUBSTANCE P MARKET SIZE, BY BIOMARKER IDENTIFICATION, 2018-2030 (USD MILLION)
TABLE 334. EGYPT SUBSTANCE P MARKET SIZE, BY PRODUCT FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 335. EGYPT SUBSTANCE P MARKET SIZE, BY INJECTABLE FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 336. EGYPT SUBSTANCE P MARKET SIZE, BY DELIVERY TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 337. EGYPT SUBSTANCE P MARKET SIZE, BY NANOTECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 338. EGYPT SUBSTANCE P MARKET SIZE, BY INSTITUTIONAL COLLABORATIONS, 2018-2030 (USD MILLION)
TABLE 339. EGYPT SUBSTANCE P MARKET SIZE, BY INDUSTRY STAKEHOLDERS, 2018-2030 (USD MILLION)
TABLE 340. EGYPT SUBSTANCE P MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 341. EGYPT SUBSTANCE P MARKET SIZE, BY REGULATORY AND P

Companies Mentioned

  • AAPPTec
  • AnaSpec Inc
  • Bachem Holding AG
  • Biosynth
  • Biotage AB
  • CPC Scientific Inc
  • Creative Diagnostics LLC
  • CSBio Inc
  • GenScript Biotech Corporation
  • Lonza Group Ltd
  • Merck KGaA
  • Neuland Laboratories Limited
  • PolyPeptide Group AG
  • Thermo Fisher Scientific Inc

Related Topics

Related Reports

Drug Compounding System Market - Global Forecast 2026-2032 - Product Image

Drug Compounding System Market - Global Forecast 2026-2032

  • Report
  • 199 Pages
  • Global
From
Antiparasitic Drugs Market - Global Forecast 2026-2032 - Product Image

Antiparasitic Drugs Market - Global Forecast 2026-2032

  • Report
  • 187 Pages
  • Global
From
Antidotes - Global Strategic Business Report - Product Image

Antidotes - Global Strategic Business Report

  • Report
  • 381 Pages
  • Global
From
Antidotes Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Antidotes Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Antidotes Market Report 2026 - Product Image

Antidotes Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.